IMVT - Immunovant Inc logo

IMVT

Immunovant Inc

Rev —top 1%5Y
Hold

Immunovant develops monoclonal antibodies targeting autoimmune diseases, focusing on conditions like Graves' disease, rheumatoid arthritis, and myasthenia gravis. Its pipeline includes IMVT-1402 and batoclimab, aimed at providing targeted therapeutic solutions.

⚕️ Healthcare NASDAQ Listed 2019 $ USD
$1,000 invested 5 years ago $5,233today

Score Overview

1 Year
Score
Net Growth-22.17%
Net TrendShrank
Net Income Consistency
Rev Growth
Rev TrendShrank
Revenue Consistency
5 Years
Score
Net Growth-370.63%
Net TrendNever
Net Income Consistency
Rev Growth
Rev TrendNever
Revenue Consistency
All Time
Score
Net Growth-5x
Net TrendNever
Net Income Consistency
Rev Growth
Rev TrendNever
Revenue Consistency

See the full market ranking →

Immunovant Inc fundamental performance

Across Immunovant Inc's full reported history, from 2020 to 2026, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 66M to -$ 505M. Revenue increased in 0% of the years measured; net income in 0%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 42.60
1 Year2025-08-12
$ 15.21180.08%
5 Years2021-08-12
$ 8.14423.34%
All Time2019-06-21
$ 9.95328.14%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 505M$ 902M
2025$ 0.00-$ 413M$ 713M
2024$ 0.00-$ 259M$ 635M
2023$ 0.00-$ 210M$ 376M
2022$ 0.00-$ 156M$ 493M
2021$ 0.00-$ 107M$ 400M
2020$ 0.00-$ 66M$ 100M

Explore beyond IMVT

You're looking at Immunovant Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies